The most important Brazilian event on Lymphoproliferative Diseases

REGISTER NOW

About The Conference:

The 14th edition of the Brazilian Lymphoma Conference (BLC 2024), a 3 1/2-day conference, will be held exclusively online from April 24-27. As a result of many people's work, the BLC has become the most significant event on lymphoproliferative diseases in Latin America due to the number of attendees and the acknowledgment of national and international experts. The updated scientific content, mainly focusing on the remarkable advances already published or submitted at recent meetings, presents a critical view of these studies, particularly in their relevance in countries with less financial resources, given the high cost of these new treatments.

Main Topics:
  • Agressive Lymphomas
  • Mantle Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Peripheral T-cell Lymphomas
  • Hodgkin Lymphoma
  • Access to novel therapies for onco-hematological diseases
  • Lymphoproliferative diseases: issues in evidence
  • Clinical Case Presentation


    • • Joint Session: Brazilian Lymphoma Conference (BLC) & Grupo de Estudo Latinoamericano de Linfoproliferativos (GELL): Understanding our common problems
    • Hot topics: NK Cells and Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies
    • Key-note Conference: Circulating Tumor DNA in Lymphoma: Principles and Future Directions.





    President

    Carlos Sérgio Chiattone

    Director of Institutional Relations at ABHH
    Professor at the Faculty of Medical Sciences of Santa Casa de São Paulo
    Hospital Samaritano

    Organizing Committeee

    Celso Arrais
    UNIFESP/ Hospital 9 de Julho
    Guilherme Perini
    Hospital Israelita Albert Einstein e Grupo Américas
    Jorge Vaz Pinto Neto
    Cettro (Centro de Cancer de Brasília)
    Natalia Zing
    BP A Beneficência Portuguesa de São Paulo
    Talita Silveira
    AC Camargo Cancer Center
    Thais Fisher
    AC Camargo Cancer Center

    Speakers



    ...
    Adam J. Olszewski

    Brown University

    ...
    Adriana Scheliga

    Grupo Oncoclínicas

    ...
    Alan Skarbnik

    University of North Carolina at Chapel Hill School of Medicine

    ...
    Alexey Danilov

    City of Hope National Medical Center

    ...
    Alison J. Moskowitz

    Memorial Sloan Kettering Cancer Center

    ...
    Alvaro Alencar

    University of Miami

    ...
    André Neder Ramires Abdo

    ICESP e Hospital Alemão Oswaldo Cruz

    ...
    Ash Alizadeh

    Stanford University School of Medicine

    ...
    Christine Ryan

    Harvard Medical School

    ...
    Dani Laks

    Hospital Moinhos de Vento

    ...
    Danielle Leão

    Hospital BP - A Beneficência Portuguesa de São Paulo

    ...
    Emanuele Zucca

    Oncology Institute of Southern Switzerland, Ospedale San Giovanni

    ...
    Felipe D Almeida

    Sociedade Brasileira de Patologia

    ...
    Guilherme Perini

    Hospital Israelita Albert Einstein e Grupo Américas

    ...
    Izidore Lossos

    University of Miami

    ...
    Jacob Soumerai

    Massachusetts General Hospital Cancer Center

    ...
    Jayr Schmidt Filho

    A.C Camargo Cancer Center

    ...
    Jorge Vaz Pinto Neto

    Grupo Oncoclínicas

    ...
    José Cabeçadas

    IPO Lisboa

    ...
    José Sandoval

    Moffitt Cancer Center

    ...
    Juliana Pereira

    FMUSP

    ...
    Kalysta Borgers

    ONCOLÓGICA TAPAJÓS

    ...
    Karina Corrêa Barcelos

    Grupo OncoClínicas e Unimed Vitória

    ...
    Larissa Gandolpho

    EPM / UNIFESP

    ...
    Luis Malpica Castillo

    MD Anderson Cancer Center

    ...
    Maria Almeida Dias

    Universidade Federal da Bahia

    ...
    Massimo Federico

    Università degli Studi di Modena e Reggio Emilia

    ...
    Natália Zing

    BP - A Beneficência Portuguesa de São Paulo

    ...
    Patricia Giacon

    Hospital Santa Marcelina

    ...
    Paul Bröckelmann

    University Hospital of Cologne, Germany German Hodgkin Study Group (GHSG)

    ...
    Rafael Dezen Gaiolla

    UNESP

    ...
    Stefano Luminari

    University of Modena and Reggio Emilia

    ...
    Stefano Pileri

    Bologna University and European Institute of Oncology

    ...
    Sven Borchmann

    University of Cologne

    ...
    Talita Silveira

    AC Camargo Cancer Center

    ...
    Thais Fischer

    AC Camargo Cancer Center

    ...
    Vanderson Rocha

    FMUSP

    ...
    Yung Bruno de Mello Gonzaga

    Instituto Nacional de Cancer e Grupo Oncoclínicas

    Registration

    Registration

    ABHH Member


    Free

    (*2023/24 paid annuity)

    "You must use the email and password you registered with to access the conference broadcasting platform."

    NON-MEMBER


    $40,00*


    * Registration will only be effective after payment has been confirmed. You must use the email and password you registered to access the conference-broadcasting plataform.

    Withdrawal and Reimbursement

    • The request for registration cancelation and reimbursement should be sent to the Secretariat until April 20, 2024. After this date, no cancelation will be accepted.
    Reimbursement for the amount paid will be made up to 60 days after the conference and it will correspond to 60% of the amount paid..
    • Click here to download the request for reimbursement.
    • Please send the request properly signed and scanned to the email: eventos@abhh.org.br


    Simultaneous Translation


    International speakers’ lectures and Live sessions of Questions and Answers will rely on simultaneous translation (English/Portuguese).
    Please select the language-corresponding button on the upper corner of the screen.

    Scientific Programme

    Wednesday, April 24th

    13:30 - 13:40
    Opening
    President ABHH: Angelo Maiolino (BRA)
    Chair Brazilian Lymphoma Conference: Carlos Sérgio Chiattone (BRA)
    13:40 - 14:40
    Session 1 / Aggressive Lymphomas I
    Moderators: Guilherme Perini & Rafael Dezen Gaiolla (BRA)
    13:40 - 14:00
    New data on biological heterogeneity in Diffuse Large B-cell Lymphoma
    José Cabeçadas (PRT)
    14:00 - 14:20
    A critical vision on treatment of newly diagnosed Diffuse Large B-cell Lymphoma
    Speaker: Adam J. Olszewski (USA)
    14:20 - 14:40
    Live Q&A session
    14:40 - 15:40
    Session 2: Aggressive Lymphomas II
    moderators: Vanderson Rocha (BRA) & Daniel Tabak (BRA)
    14:40 - 15:00
    Diffuse Large B cell Lymphomas R/R: Why thinking in bispecific antibodies?
    Izidore Lossos (USA)
    15:00 - 15:20
    Diffuse Large B cell Lymphoma R/R: Why thinking in CAR-T cell Therapy?
    Alvaro Alencar (USA)
    15:20 - 15:40
    Live Q&A session
    15:40 - 16:00
    Break
    16:00 - 16:45
    Corporate Symposium - Abbvie
    (Only prescribers) 'Off-the-shelf' immunotherapy and its importance in combating Diffuse Large B Cell Lymphoma 3L+
    Speaker: Juliana Pereira (BRA)
    16:45 - 17:00
    Break
    17:00 - 17:45
    Corporate Symposium - Kite
    (Only prescribers) CAR-T approved in second line for LBCL: what changes in my clinical practice?
    Speaker: Vanderson Rocha (BRA) / Moderator: Natália Zing (BRA)
    17:45 - 19:05
    Session 3: Special situations in Aggressive Lymphomas (Clinical Case Presentation)
    Moderators: Diego Villa Clé (BRA) & Guilherme Duffles (BRA)
    17:45 - 18:00
    Diffuse Large B cell Lymphoma in elderly: one size fits all?
    Jorge Vaz Pinto Neto (BRA)
    18:00 - 18:15
    Burkitt
    Karina Corrêa Barcelos (BRA)
    18:15 - 18:30
    Gastric Diffuse Large B cell Lymphoma
    Speaker: Natalia Zing (BRA)
    18:30 - 18:45
    Richter transformation
    Dani Laks (BRA)
    18:45 - 19:05
    Live Q&A session

    Thursday, April 25th

    12:30 - 13:15
    Corporate Symposium - Roche
    (Only prescribers) Treatment paradigms - 1L DLBCL therapeutical Evolution
    Speaker: Jayr Schmidt Filho
    13:15 - 13:30
    Break
    13:30 - 14:15
    Corporate Symposium - Lilly
    (Only prescribers) Third-line MCL treatment: reversible BTK inhibition has arrived
    Moderator: André Abdo (BRA)
    Speaker: Alvaro Alencar
    14:15 - 15:15
    Session 4: Mantle Cell Lymphoma
    Moderators: Sergio Brasil (BRA) & Rony Schaffel (BRA)
    14:15 - 14:35
    How to treat high risk Mantle Cell Lymphoma?
    Jacob Soumerai (USA)
    14:35 - 14:55
    Mantle Cell Lymphoma post BTKi: New horizons
    José Sandoval (USA)
    14:55 - 15:15
    Live Q & A session
    15:15 - 16:15
    Session 5: Chronic Lymphocytic Leukemia
    Moderators: Celso Arrais (BRA) & Ricardo Bigni (BRA)
    15:15 - 15:35
    Game of thrones in CLL: which 1st line therapy will survive?
    Christine Ryan (USA)
    15:35 - 15:55
    BTK inhibitors covalent and non-covalent: what should we know in CLL treatment?
    Alexey Danilov (USA)
    15:55 - 16:15
    Live Q & A session
    16:15 - 16:30
    Break
    16:30 - 17:15
    Corporate Symposium - Janssen
    (Only prescribers) Diagnosis and treatment in Rare Lymphomas
    Patricia Giacon (BRA) & Felipe D'Almeida (BRA)
    17:15 - 18:15
    Session 6: Follicular Lymphoma
    Moderators: Jacques Tabacof (BRA) & Marcelo Bellesso (BRA)
    17:15 - 17:35
    New clinical and biological prognostic factors
    Stefano Luminari (ITA)
    17:35 - 17:55
    Treatment of Follicular Lymphoma refractory/early relapsed: how I do my choices?
    Massimo Federico (ITA)
    17:55 - 18:15
    Live Q&A
    18:15 - 19:15
    Session 7: Peripheral T-cell Lymphomas
    Moderators: Ruddy Dalfeor (BRA) & André Néder Ramires Abdo (BRA)
    18:15 - 18:35
    Pathobiology of Nodal Peripheral T-cell Lymphomas
    Stefano Pileri (ITA)
    18:35 - 18:55
    Adult T-cell Leukemia/Lymphoma: Data from the T-cell Brazil Project
    Yung Bruno de Mello Gonzaga (BRA)
    18:55 - 19:15
    Live Q & A session
    19:15 - 19:30
    Break
    19:30 - 20:15
    Corporate Symposium - Takeda (Only prescribers) The Great Debate About Peripheral T-Cell Lymphomas
    Moderator: Carlos Chiattone (BRA)
    Speakers: André Neder Ramires Abdo (BRA) & Thais Rodrigues Fischer (BRA)

    Friday, April 26th

    12:15 - 13:15
    Session 8: Hodgkin Lymphoma
    Moderator: Marco Aurélio Salvino (BRA) & Talita Silveira
    12:15 - 12:35
    Which is the new standard treatment for first line advanced Hodgkin Lymphoma?
    Speaker: Paul Bröckelmann (GER)
    12:35 - 12:55
    How to face Hodgkin Lymphoma refractory to checkpoint inhibitor and conjugate antibodies?
    Alisson Moskowitz (USA)
    12:55 - 13:15
    Live Q & A session
    13:15 - 13:30
    Break
    13:30 - 14:15
    Corporate Symposium - Knight Therapeutics
    (Only prescribers) Update on Diffuse Large B-Cell Lymphoma (DLBCL) - Clinical Case Discussion
    Speakers: Alan Skarbnik (USA) & Guilherme Perini (BRA)
    14:15 - 14:30
    Break
    14:30 - 15:15
    Corporate Symposium - MSD
    (Only prescribers) Case Studies: Improving the Stages in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma
    Adriana Scheliga (BRA) and Talita Silveira (BRA)
    15:15 - 16:15
    Joint Session 9: Brazilian Lymphoma Conference (BLC) & Grupo de Estudo Latinoamericano de Linfoproliferativos (GELL): Understanding our common problems
    Moderators: Henry Idrobo-Quintero (COL) & Carlos Chiattone
    15:15 - 15:35
    How to bring more clinical trials to Latin America?
    Luis Malpica Castillo (USA)
    15:35 - 15:55
    Epidemiological, clinical features, and outcomes of Peripheral T cell Lymphomas in Latin-American
    Thais Fischer (BRA)
    15:55 - 16:15
    Live Q & A session
    16:15 - 16:30
    Break
    16:30 - 17:15
    Corporate Symposium - Beigene (Only prescribers) Importance of using BTKi(s) in the sequencing of RR Mantle Cell Lymphoma Treatment
    Speaker: André Néder Ramires Abdo (BRA)
    17:15 - 18:00
    Session 10: Access to novel therapies for onco-hematological diseases
    Moderators: Carmino Antonio de Souza (BRA) & Angelo Maiolino (BRA)
    17:15 - 17:35
    Brazilian Association of Hematology, Hemotherapy and Cell Therapy (ABHH) structure and activities with agencies incorporating new technologies
    Jorge Vaz Pinto Neto (BRA)
    17:35 - 18:00
    Live Q & A session

    Saturday, April 27th

    08:00 - 09:00
    Session 11: Lymphoproliferative diseases: issues in evidence
    Moderators: Wellington Azevedo (BRA) & Marcos Daniel de Deus Santos (BRA)
    08:00 - 08:20
    Nodular lymphocytic predominance Hodgkin Lymphoma: treatment and follow-up
    Speaker: Sven Borchmann (GER)
    08:20 - 08:40
    Splenic Marginal Zone Lymphoma: What is new?
    Emanuele Zucca (CH)
    08:40 - 09:00
    Live Q & A session
    09:00 - 10:20
    Session 12: Lymphomas and CLL: 2023 Review
    Moderators: Belinda Simões (GER) & Samir Kanaan Nabhan (BRA)
    09:00 - 09:20
    Chronic Lymphocytic Leukemia
    Adriana Scheliga (BRA)
    09:20 - 09:40
    Aggressive Lymphomas
    Danielle Leão (BRA)
    09:40 - 10:00
    Indolent Lymphomas
    Maria Almeida Dias (BRA)
    10:00 - 10:20
    Live Q & A session
    10:20 - 11:10
    Key-note Conference
    Moderator: Otávio Baiocchi (BRA)
    10:20 - 10:50
    Circulating tumor DNA in Lymphoma: Principles and future directions
    Ash A. Alizadeh (San Francisco, CA)
    10:50 - 11:10
    Live Q & A session
    11:10 - 12:10
    Session 13: Hot Topics
    Moderators: Jayr Schmidt Filho (BRA) & Renato Cunha (BRA)
    11:10 - 11:30
    NK Cells
    Lucila Kerbauy (BRA)
    11:30 - 11:50
    Managing the risk of infection in Chronic Lymphocytic Leukemia in the era of new therapies
    Larissa Gandolpho (BRA)
    11:50 - 12:10
    Onco-hematological diseases in Brazilian Amerindians
    Speaker: Kalysta Borges (BRA)
    12:10 - 12:30
    Live Q & A session
    12:30 - 12:40
    Closing
    Chair BLC: Carlos Chiattone (BRA)

    * The content of some Corporate Symposia is only for attendees based on the compliance policy of each company promoting the activity.

    General Infotmation

    The access to the broadcasting platform will be through the link, please use the data entered at registration (email and password). You will be able to access it from April 23th.

    Please access our chat, on the bottom right icon of the website. If you prefer, you can reach us through email: eventos@abhh.org.br
    In case you need support during the broadcasting, our communication channels will be available.

    If you are trying to enter your password but it is not right, you should be driven to other page to recover your password.

    Please try again or use a different email address you often use.

    A certificate will be awarded to all attendees. It should be available 7 days after the event. Please access the Restricted Area of this website using your email and password registered.
    *It is mandatory to have attended to 70% of total workload of the conference.

    Follow the event in real time. For ABHH members, classes will be available at Hemoteca: https://aulas.abhh.srv.br/hemoteca/ approximately 10 days after the event. For other registrants, classes will be made available approximately 30 days after the event. The event organization will send an email with the access link and voucher.

    • Use the Google Chrome browser.
    • Check if the place chosen has a good internet signal and if your computer battery is loaded (or make sure you are close to a power source).
    • Test your connection through the internet address: www.speedtest.net
    • If you are using the company computer, it may have safety protocols that might interfere. If that is the case, please use your personal computer.
    • Choose your desktop over a tablet or mobile device.
    • Close all the windows and software not necessary to access the event.
    • Make sure every pop-up blockage software on your browser is off.
    • Remember to disable the VPN in your computer settings.
    • Try an incognito window on your web browser..
    • Choosing a calm place, and if possible a quiet place, will help in your concentration.
    • Access the conference link 1 hour in advance, so you can check the places available in the platform.
    • Use the programme breaks to stretching, drinking some water, checking your messages, etc.
    • Remember to interact through the chat and interaction tools.

    ANVISA (Agência Nacional de Vigilância Sanitária)
    RDC 102 - Medicamentos / RDC 96 - Cod. de conduta
    Sessão 6 - Item 6.6.2 - Apoio ao profissional de saúde

    Sponsorships


    Gold


    Silver


    Bronze


    Support


    Institutional support